Some MHCII may be transferred from your MVB-delimiting membrane to the lysosomal-delimiting membrane and from there to the plasma membrane to present lysosomal-generated peptides (8). now allowing its transfer to the cell surface. This mode of regulation for MHCII is usually a prime example of how molecular processing and sorting at multivesicular body can determine the expression of signaling receptors at the plasma membrane. Antigen presentation by dendritic cells is usually regulated through intracellular processing and trafficking of MHCII. These sorting mechanisms are instrumental in directing specificity in adaptive immune responses. Dendritic cells (DCs) are present throughout peripheral tissues, where they constitutively sample their environment for the presence of pathogens and diseased cells through uptake of soluble and particulate matter by endocytic mechanisms, including clathrin-mediated endocytosis, phagocytosis, macropinocytosis, and trogocytosis. Trogocytosis refers to uptake of membrane and associated molecules from one cell by another. After endocytic uptake, both environmental self proteins and proteins from pathogenic origin can be processed into peptides for loading onto major histocompatibility complex (MHC) molecules. Peptides can be generated either by lysosomal proteases in the endocytic pathway, or by proteasomes when endocytosed proteins are transferred across the endosomal membrane into the cytosol. Thus, generated peptides may associate intracellularly with either MHC class I (MHCI) or MHC class II (MHCII) molecules, and in that context can be transferred to and displayed at the plasma membrane. MHCpeptide complexes can be recognized by T cells upon migration of DCs to lymphoid tissues (Guermonprez et al. 2002). In the absence of danger signals, DCs remain in a resting or immature state and display endogenous self peptides to maintain peripheral tolerance (Steinman et al. 2003;Schmidt et al. 2012). However, DCs also survey their environment with a collection of innate pattern-recognition receptors (PRRs), including Toll-like receptors (TLR), C-type lectins, and nucleotide oligomerization domain name (NOD)like receptors, which collectively identify a wide array of conserved pathogen-associated molecular patterns (PAMPs) and damage-associated molecular patterns (DAMPs), with the latter representing (altered) self molecules that are released by dying cells or expressed by tumor cells. DCs that are activated through their PRRs or by inflammatory cytokines differentiate into phenotypes that can stimulate adaptive immune responses (Reis e Sousa 2006;Joffre et al. 2009). Characteristic features of DC differentiation or maturation include a transient increase in phagocytosis and macropinocytosis for efficient antigen uptake, increased surface expression of costimulatory molecules (e.g., CD86, CD80, CD40), and enhanced potential to migrate from peripheral tissues to the local lymphoid tissues for LXH254 conversation with T cells (West et al. 2004;Reis e Sousa 2006). Several other stimuli, for TSPAN11 example, TNF-, can drive option DC maturation programs that result in tolerogenic rather than immunogenic DCs (Menges et al. 2002;Tan and ONeill 2005;Cools et al. 2007;Maldonado and von Andrian 2010). MHC molecules direct antigen specificity for adaptive immunity toward invading pathogens and malignant cells. LXH254 MHCI on DCs predominantly helps removal of infected and malignant cells through activation of antigen-specific CD8+cytotoxic T cells. MHCI-driven cell killing by cytotoxic T cells, however, also requires licensing by DCs through MHCII-dependent activation of CD4+helper T cells. In addition, MHCII on DCs serves to mount humeral immune responses and to instruct regulatory T cells and memory T cells. In contrast to MHCII, MHCI is usually expressed by nearly all cell types, and in nonprofessional antigen-presenting cells is usually exclusively loaded with peptides that are generated from cytosolic LXH254 proteins by the ubiquitin/proteasome system. Cytosolic peptides can be translocated into the lumen of the endoplasmic reticulum (ER) for loading onto MHCI with the help of a dedicated peptide-loading complex (Cresswell et al. 2005). Peptide-loaded MHCI is usually then transported out of the ER via the Golgi apparatus to the plasma membrane, where it is stably uncovered. Infected cells that display pathogen-derived peptides on MHCI can be killed by cytotoxic T cells that specifically identify relevant LXH254 MHCIpeptide complexes..